Cytomegalovirus (CMV) is the most common infection after organ transplantation and has a
major impact on morbidity, mortality and graft survival. Optimal prevention, diagnosis and …

Cytomegalovirus (CMV) infection remains a major complication of solid organ
transplantation. Because of management of CMV is variable among transplant centers, in …

Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ
transplantation, resulting in significant morbidity, graft loss, and adverse outcomes …

Cytomegalovirus (CMV) infections are among the most common infections that occur
following solid organ transplantation. CMV disease ranges from asymptomatic viremia, to …

Transplant recipients receiving immunosuppressive therapy are at increased risk of active
cytomegalovirus (CMV) infection and disease. Without appropriate prophylaxis, as many as …

Cytomegalovirus infection remains a major complication of solid organ transplantation. In
2005 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society …

Abstract (See the editorial commentary by Avery, on pages 322-324.) Background.
Valganciclovir (VGC) 900 mg is approved for CMV prophylaxis, but it has been associated …

We systematically reviewed and meta-analyze the efficacy of universal prophylaxis (UP) and
preemptive (PE) strategies (using ganciclovir or valganciclovir) in preventing …

Advances in surgical technique, critical care, immunosuppression, donor and recipient
screening, and prophylactic strategies have contributed to the evolving microbiology and …

Purpose The purpose of this study was to compare the safety and efficacy of two
valganciclovir (VGCV) institutional dosing protocols for cytomegalovirus (CMV) prophylaxis …